Simon Glairy is a seasoned authority in risk assessment and insurance technology, often navigating the complex intersections of insurance law and systemic fraud. His expertise in identifying fraudulent patterns provides a unique lens through which we can examine the recent $1.2 million lawsuit filed by GEICO against a Queens-based pharmacy. This interview explores the nuances of New York’s No-Fault system, the specific exploitation of pharmaceutical pricing schedules, and the sophisticated tactics used to bypass institutional oversight in the pursuit of illicit profits. We delve into the mechanics of how high-priced topical creams become the center of massive billing schemes and the red flags that eventually lead to legal intervention.
The massive price disparity between specialized prescription pain creams and everyday drugstore alternatives is staggering. How does a pharmacy justify billing thousands of dollars for a product that has a ten-dollar equivalent on a retail shelf?
It is a calculated manipulation of the Pharmacy Fee Schedule that hinges on the Average Wholesale Price of very specific formulations. In this case, the pharmacy was billing $2,686.88 for Diclofenac Sodium 2% and over $2,217 for Lidocaine ointment, even though you can walk into a Rite-Aid and find something functionally similar for just $10. By selecting these high-priced products intentionally, the pharmacy ensured that 75% of its total billing—reaching more than $920,000—came from just a handful of these topical items. This creates a massive profit margin that ignores the medical necessity of the price point in favor of hitting the $50,000 per-person limit allowed under New York’s No-Fault benefits. It is a sensory overload of corporate greed where the numbers simply do not align with the reality of patient care or standard market value.
GEICO mentioned that the pharmacy utilized numerous expedited arbitrations to pursue payment. Why is this fragmented approach so effective for those attempting to hide a larger fraudulent scheme?
This is a tactic designed to “hide in the noise” of the legal system by preventing any single authority from seeing the bigger picture. By filing separate, expedited No-Fault arbitrations, the pharmacy ensures that no single arbitrator sees the full $1.2 million scope of the operation that occurred within that brief two-month window. It is a tactical move to keep the focus on individual, small-scale claims rather than the collective $583,000 that GEICO is now fighting to recover. When cases are handled piece-meal, insurance legal teams are forced to fight hundreds of tiny fires rather than addressing the arsonist responsible for the entire blaze. This strategy intentionally masks the “large, ongoing fraudulent scheme” described in the complaint, making it much harder for a human reviewer to flag the systemic abuse of the reimbursement caps.
The investigative red flags in this case, such as patients living far from the pharmacy or delays in filling scripts, seem quite obvious in hindsight. What do these indicators tell us about the logistical side of insurance fraud?
These red flags are the “fingerprints” of a collusive relationship between the pharmacy and certain prescribers who are likely receiving financial incentives. When 90% of your patients live outside of Queens or even out of state, it is a clear sign that prescriptions are not being filled based on convenience, but rather through a pre-arranged referral network. The fact that the exact same set of high-priced drugs was prescribed to multiple people from a single car crash suggests a “template” for billing rather than individualized healthcare. Furthermore, when a prescription sits for weeks before being filled, it loses the urgency of genuine pain management and starts looking like a cold, calculated financial transaction. These patterns are exactly what modern risk assessment tools are designed to catch before the bill reaches into the millions and the pharmacy suddenly stops operating.
Filing a lawsuit under the Racketeer Influenced and Corrupt Organizations Act is an intense legal move. What does the pursuit of treble damages signify about the severity of these allegations?
Invoking RICO is a signal that the carrier believes this was not just a series of administrative mistakes, but a coordinated criminal enterprise. By aiming for treble damages, the filing pegs the recovery figure at approximately $1,749,000, which is nearly triple the amount GEICO actually paid out. This strategy is designed to be a powerful deterrent, sending a message to other pharmacies that exploiting the New York Public Health Law regarding kickbacks carries a devastating financial penalty. It transforms a standard fraud case into a high-stakes legal battle over the very integrity of the No-Fault insurance system. It also brings intense heat to the “Prescribers” and the illegal referral relationships that allegedly fueled the entire $1.2 million billing spree.
What is your forecast for the future of No-Fault insurance fraud detection as pharmacies and clinics continue to find new ways to inflate bills?
I expect we will see a much more aggressive push toward centralized data tracking to prevent the kind of “piece-meal” arbitration tactics used in this $1.2 million scheme. As carriers realize that nearly $1 million can be drained in just two months before a pharmacy vanishes, they will likely implement real-time alerts for any entity that shows a sudden, massive spike in billing for high-AWP topical products. The focus will shift toward exposing the “Prescribers” and the illegal referral networks that the GEICO filing highlighted but did not yet name as defendants. Ultimately, the industry must move toward a model where pharmaceutical billing is tied more closely to regional retail averages rather than allowing single-owner pharmacies to exploit the fee schedule for thousands of dollars per tube of gel. The fight against fraud is becoming a war of data, where the ability to see the “whole pattern” across multiple jurisdictions will be the only way to protect the financial stability of the system.
